Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Proliferation Tumour Marker Network (PTM-NET) for the identification of tumour region in Ki67 stained breast cancer whole slide images.

Joseph J, Roudier MP, Narayanan PL, Augulis R, Ros VR, Pritchard A, Gerrard J, Laurinavicius A, Harrington EA, Barrett JC, Howat WJ.

Sci Rep. 2019 Sep 6;9(1):12845. doi: 10.1038/s41598-019-49139-4.

2.

Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA.

Rowlands V, Rutkowski AJ, Meuser E, Carr TH, Harrington EA, Barrett JC.

Sci Rep. 2019 Sep 2;9(1):12620. doi: 10.1038/s41598-019-49043-x.

3.

A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.

Eyre TA, Hildyard C, Hamblin A, Ali AS, Houlton A, Hopkins L, Royston D, Linton KM, Pettitt A, Rule S, Cwynarski K, Barrington SF, Warbey V, Wrench D, Barrans S, Hirst CS, Panchal A, Roudier MP, Harrington EA, Davies A, Collins GP.

Hematol Oncol. 2019 Aug 5. doi: 10.1002/hon.2662. [Epub ahead of print]

PMID:
31385336
4.

Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial.

Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PG, Odegaard JI, Harrington EA, Lee J, Lee T, Oh SY, Kang JH, Kim JH, Kim Y, Ji JH, Kim YS, Lee KE, Kim J, Sohn TS, An JY, Choi MG, Lee JH, Bae JM, Kim S, Kim JJ, Min YW, Min BH, Kim NKD, Luke S, Kim YH, Hong JY, Park SH, Park JO, Park YS, Lim HY, Talasaz A, Hollingsworth SJ, Kim KM, Kang WK.

Cancer Discov. 2019 Jul 17. pii: CD-19-0442. doi: 10.1158/2159-8290.CD-19-0442. [Epub ahead of print]

PMID:
31315834
5.

pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.

Jones GN, Rooney C, Griffin N, Roudier M, Young LA, Garcia-Trinidad A, Hughes GD, Whiteaker JR, Wilson Z, Odedra R, Zhao L, Ivey RG, Howat WJ, Harrington EA, Barrett JC, Ramos-Montoya A, Lau A, Paulovich AG, Cadogan EB, Pierce AJ.

Br J Cancer. 2018 Nov;119(10):1233-1243. doi: 10.1038/s41416-018-0286-4. Epub 2018 Nov 2.

6.

Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.

Paoletti C, Schiavon G, Dolce EM, Darga EP, Carr TH, Geradts J, Hoch M, Klinowska T, Lindemann J, Marshall G, Morgan S, Patel P, Rowlands V, Sathiyayogan N, Aung K, Hamilton E, Patel M, Armstrong A, Jhaveri K, Im SA, Iqbal N, Butt F, Dive C, Harrington EA, Barrett JC, Baird R, Hayes DF.

Clin Cancer Res. 2018 Dec 1;24(23):5860-5872. doi: 10.1158/1078-0432.CCR-18-1569. Epub 2018 Aug 6.

PMID:
30082476
7.

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.

Basu B, Krebs MG, Sundar R, Wilson RH, Spicer J, Jones R, Brada M, Talbot DC, Steele N, Ingles Garces AH, Brugger W, Harrington EA, Evans J, Hall E, Tovey H, de Oliveira FM, Carreira S, Swales K, Ruddle R, Raynaud FI, Purchase B, Dawes JC, Parmar M, Turner AJ, Tunariu N, Banerjee S, de Bono JS, Banerji U.

Ann Oncol. 2018 Sep 1;29(9):1918-1925. doi: 10.1093/annonc/mdy245.

8.

An advanced pharmacy practice experience in academia: More benefit than burden!

Harrington EA, Gawronski KM.

Curr Pharm Teach Learn. 2018 Apr;10(4):399-402. doi: 10.1016/j.cptl.2017.12.022. Epub 2018 Jan 17.

PMID:
29793699
9.

Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.

Avivar-Valderas A, McEwen R, Taheri-Ghahfarokhi A, Carnevalli LS, Hardaker EL, Maresca M, Hudson K, Harrington EA, Cruzalegui F.

Oncotarget. 2018 Apr 20;9(30):21444-21458. doi: 10.18632/oncotarget.25118. eCollection 2018 Apr 20.

10.

Clinically impactful differences in variant interpretation between clinicians and testing laboratories: a single-center experience.

Bland A, Harrington EA, Dunn K, Pariani M, Platt JCK, Grove ME, Caleshu C.

Genet Med. 2018 Mar;20(3):369-373. doi: 10.1038/gim.2017.212. Epub 2017 Dec 14.

PMID:
29240077
11.

Nucleic acid extraction from formalin-fixed paraffin-embedded cancer cell line samples: a trade off between quantity and quality?

Seiler C, Sharpe A, Barrett JC, Harrington EA, Jones EV, Marshall GB.

BMC Clin Pathol. 2016 Nov 14;16:17. doi: 10.1186/s12907-016-0039-3. eCollection 2016.

12.

Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors.

Brant R, Sharpe A, Liptrot T, Dry JR, Harrington EA, Barrett JC, Whalley N, Womack C, Smith P, Hodgson DR.

Clin Cancer Res. 2017 Mar 15;23(6):1471-1480. doi: 10.1158/1078-0432.CCR-16-0021. Epub 2016 Oct 12.

13.

Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon.

Rooney C, Geh C, Williams V, Heuckmann JM, Menon R, Schneider P, Al-Kadhimi K, Dymond M, Smith NR, Baker D, French T, Smith PD, Harrington EA, Barrett JC, Kilgour E.

PLoS One. 2016 Feb 23;11(2):e0149628. doi: 10.1371/journal.pone.0149628. eCollection 2016.

14.

Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.

Harrington EA, Sloan JL, Manoli I, Chandler RJ, Schneider M, McGuire PJ, Calcedo R, Wilson JM, Venditti CP.

Hum Gene Ther. 2016 May;27(5):345-53. doi: 10.1089/hum.2015.092. Epub 2016 Mar 22.

15.

Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples.

Veldman-Jones MH, Brant R, Rooney C, Geh C, Emery H, Harbron CG, Wappett M, Sharpe A, Dymond M, Barrett JC, Harrington EA, Marshall G.

Cancer Res. 2015 Jul 1;75(13):2587-93. doi: 10.1158/0008-5472.CAN-15-0262. Epub 2015 Jun 11. Review.

16.

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

Basu B, Dean E, Puglisi M, Greystoke A, Ong M, Burke W, Cavallin M, Bigley G, Womack C, Harrington EA, Green S, Oelmann E, de Bono JS, Ranson M, Banerji U.

Clin Cancer Res. 2015 Aug 1;21(15):3412-9. doi: 10.1158/1078-0432.CCR-14-2422. Epub 2015 Mar 24.

17.

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.

Hancox U, Cosulich S, Hanson L, Trigwell C, Lenaghan C, Ellston R, Dry H, Crafter C, Barlaam B, Fitzek M, Smith PD, Ogilvie D, D'Cruz C, Castriotta L, Wedge SR, Ward L, Powell S, Lawson M, Davies BR, Harrington EA, Foster E, Cumberbatch M, Green S, Barry ST.

Mol Cancer Ther. 2015 Jan;14(1):48-58. doi: 10.1158/1535-7163.MCT-14-0406. Epub 2014 Nov 14.

18.

Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System.

Veldman-Jones MH, Lai Z, Wappett M, Harbron CG, Barrett JC, Harrington EA, Thress KS.

Clin Cancer Res. 2015 May 15;21(10):2367-78. doi: 10.1158/1078-0432.CCR-14-0357. Epub 2014 Oct 9.

19.

Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.

Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, Roth JA, Li L, Gooden F, Korenchuk S, Hou XS, Harrington EA, Randolph S, Reilly JF, Ware CM, Kadin ME, Frankel SR, Richon VM.

Cancer Res. 2008 May 15;68(10):3785-94. doi: 10.1158/0008-5472.CAN-07-6091.

20.

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.

Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM.

Nat Med. 2004 Mar;10(3):262-7. Epub 2004 Feb 22. Erratum in: Nat Med. 2007 Apr;13(4):511.

21.

ATM is a cytoplasmic protein in mouse brain required to prevent lysosomal accumulation.

Barlow C, Ribaut-Barassin C, Zwingman TA, Pope AJ, Brown KD, Owens JW, Larson D, Harrington EA, Haeberle AM, Mariani J, Eckhaus M, Herrup K, Bailly Y, Wynshaw-Boris A.

Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):871-6.

22.

pRB plays an essential role in cell cycle arrest induced by DNA damage.

Harrington EA, Bruce JL, Harlow E, Dyson N.

Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11945-50.

23.

Induction of apoptosis by the Bcl-2 homologue Bak.

Chittenden T, Harrington EA, O'Connor R, Flemington C, Lutz RJ, Evan GI, Guild BC.

Nature. 1995 Apr 20;374(6524):733-6.

PMID:
7715730
24.

c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines.

Harrington EA, Bennett MR, Fanidi A, Evan GI.

EMBO J. 1994 Jul 15;13(14):3286-95.

25.

Oncogenes and cell death.

Harrington EA, Fanidi A, Evan GI.

Curr Opin Genet Dev. 1994 Feb;4(1):120-9. Review.

PMID:
8193531
26.

Cooperative interaction between c-myc and bcl-2 proto-oncogenes.

Fanidi A, Harrington EA, Evan GI.

Nature. 1992 Oct 8;359(6395):554-6.

PMID:
1406976

Supplemental Content

Loading ...
Support Center